Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

Mo.A.271 - Mo.A.280
meet Nas Ca+ lodperndent, he(t F
chirmprzee playrr.Ne'tr do~tC~ X
th~e recruited infectious Fi~c r F Cdi
soluble CD'lirandervs FF1' Far tsir;
these plasma- irrr'ted l 1FF tI F to
ble ceavagelofc FF1viFalFn [(pep11
together.ThemoFcuuatilve 0. '
of CPDA Icl ctd Fr FFF i F p
Fed FFng [ingvacin folts, iFin F
reedtoro jo res+dI i~n1c
tin cungto theN' Ac pI. rin F F
Peter L. NFF c D.VM.FlI U ' P l)8-2 1 3,6 1. >F Q (t

Monday, July 8, 1996

lo! I hde A Wll FO[tesF~c'Fedii!t F l)( 1 F F Fu' t 'F e lf1 f e r,:'ii
00 Ftr F le ltrec HI m 10 y Clq.
)I! ' A F Oil n l rFF F i F t l! r:I ' F:
1 tF F F Ti F FFI7I i rFFF._; I -i i OFF

vi dF [lii in fF7 td I t
'i F'~' Methods:'S ho
IN r0 ord '1
ii uf irg, 'slo ' I
'iF0, iplyed by Fi" iF
'1Results: CF -,-- 'I'd
11-t I t f:! rT'F p ir)is I ll Vi 1
rpe i ir.i FL F
kn i enperFOF c:d
[[F F 01 k. F Fl o '[ h At of
I FF01e' lii peF';
'I Ir' by I OF' Ii Fnl

p M subtype A- H) and group OTo identify a limited number
vich Iow to predict the neutralization spectrum of a serum.
F:doae neitrrlzcticn spectr (INS) ace defined by the neutral-,a iled with a particular serumni(solaite)o)nOl defined set of
F"T.ve 'e i5essed beyemixing secial dilutions ([:,10 to I:1280) of
o! 'i F y HIV-1iolates and nmeasuring p24 Ag production after 7
l as'I target cells. NAT were defined as highest serum dilu)0% p24AAg inhibition. The neutralization data were
F t.,iziti ir of b otlhfHIV I group M ard 0 was observed. Spectral
F; l,,trsoraF FF7 isolates by the homology of their neutralization
01-ed8 IFNS and INS clutters whichr did not correlate with the
"icir ie 3 key HIlV-I isolates were identified which allowed to
h I thec I-I seraFto the remairnirg1I HIV- solatesThe correlation
irnd expe'rrrmoctai SNS waFs 0.90 This observatiot was further vali-, ii; fl NAT [btaired by aisecotd set of 7 ser on the 3 key

D Pp FN iI

Mo.A.27 I
REMOVAL OF V3-SPECIFIC ANTIBODIES FROM THE SERUM OF INFECTED
PATIENTS HAS MINIMAL EFFECT ON NEUTRALIZATION OF PRIMARY ISOLATES
OF CLADE E HIV-lI
'IdaltcillReelAi myr nit of her, F, 'il '~.s.D -errM J, ( F,
Pecksile MiD
Objective: To lerern "th o ( rF V F IIarlhd nr~l ' F FF eilc':F'1 ' '
Ferry c ide FVFF ir' N atsT F F' mI F' es0t itst Od r o~ [FF01 V F [ Qu. i t Ii r i a
inimalerFIFleforV30pe h F F el'' l' 'iF' drI'i rimal y,lileol i diic
Methods: Sera from 'f'HlVilroledpatenti Ii nihaii ' wire slcedrlF 'F F r-hih
level o22I poifi F an'i''d'oand adullyr yil F1i,,tr Jade'
pr iriry Ioliti' [d IV 1 Sraieni' pcioIV3- Pr i FF ldo' [bpl F FFto1 '
aimno acid ldeI V3r itiFr, 1' [F [[hT I,'11FFd Siif i FF 010 [ ir NA toF
negatv o trl eF ii ra iit [ 0F I F-1'c sir p icFredwith l aFde 0\/F Fep'iFe
Affiitypurified 'oFd E/ I ill 'yti ~iorepFFF"ntFvi'utedlli iit'' ' '1m ad
portiorni F FOFFFFOra'-' IXoFr)[F F h' or F [cyJ dplete, i'n Fo iF F r CF Fn
rifc ossi' I ar'iit odiv[1010e c 'o F ''')t' I i F o ii ' ' iron iay hr"
Neutraizain s;vittFF 00 F '" ilie [ ilith i [c[leedd F V FF' i t' F 1d rm'I
oatienr by piot: I i FF 1 00([F [ [ F I pi ' i soaI te,IcI ad[oF HIVI 1.' I:' i a 5 o -l
dilutitons s o f -r' [i Fr t ut 2 i iV l1lA ' ii F e Fir f 1[ ['I u i' 'F 'iFrs
Nere deterrminred[aPtirii 0' F Fi vi' rI p 1 Fani0"F [byFLI A.
Results: GtrFFFa '''I ot' &il p 'F ail i'Ir''r:i vi Fl =',i Fr
Serum rwit lnrFll o p f l(F O' (- f anti 'tO Fr y1-i *,' IF "0' riFf l' c F i
the i lI ti '[ 00FF3de letd.'d.i l'leii' i'iii F F 'F'-), al Fhre i t - ti F F r'az'!
two pFrOi i 7 I ilde EF v ' r 1 )0 0d 1 i, F i F iai I mi Fr F 0'1 ' 'Fl V3
depet 'dr i w '' ' l '' ''i' 'Fr)o('.I ) i l-S t e I i,; ic( ii p_!II'
V/3-II 'Ll t i Ii ii F ' r l hyi F'Ii f F) ' ' ' F ad;1, t ' ii: ' I ' i "~ n''F F
used airaFc o r''t ~ I F ' F i ~r'' F ' 1in't' lrde' F''(I rJ1
Conclusons: Ihesc d[iias ung(; F' 'F /), p F F Fntl r' e ') 1( -t' )ti 1- V 1 ' r 1'F t
NithFG [ride F I IV IcO I aI!1in il IInt. ' F '' tt Fr F iai I I Ff r la i F F F C ' F
Iee 00F o' nFF ' F [I ai r yii 4F ad('I' I ' 1,1 [ er F r F I dV" 1 tI:)lF F f I F
Fr e iii t OFFFF'rFrlizi' nih i r ',ladI EI i/II',ire FFFFFFIFFero;, I F'''tr. h"
00'eFuFl t shoud help [F lu "'F I V i Ii ', F 11 i iF 0 l, I'd No- Ic n I,~I f

fdlV I s lto
Conclusion: F ' esult F F F [y emrraI to' tfhit SNS and INS clusters do tot correlate
i p01noFtic 'rd-OuCr e ro o ofla'a1siFs0wVill fi i tate the evaluation as well as the design
of FiF"leHIV, 00 r, f it1iduce I h rto'erntrc [ide oross-teuti lizing antibodies.
PhFF[ e Npe_ir ri 'o t e of icaFMelicie, Nar erae tiF t 1SS.2000 Antwerpen, Belgium,
1e1 F?2 '3 ',14 F':x 3 2,l 3 33
Mo.A.274
INACTIVATION OF HIV- I BY RECOMBINANT ANTIBCODIES
['Fjr c' PeIAul.1 ~l,1 i.' F 'Phiib is Ill, CF.. Burton, [D.R. Cepartments of lmmunology Fed
MH ii'ul ii P F Fo The SripFpt'Reeircoh Institute, La Jolla, CA 92037.
Objective: ITo i Fisolte F1 F[ neural1in recormbinatt antibodies to HIV- I and characterize
roulri F dit F F ' 'Vir i F 1In ov"
Methods: Ani F I, 1 'F 1 i sly lOraF'i10 Nereprepared freerlorng-termnrHIV- I seropositve
1onrs In[ inFiFia ' iror Fir F 1 m onersHIV- I envelope sbuorits were used for enrichIF OF I irnd s orr y I iofcl"n'FSele01onFoIripotetcy irnd strineor oss-reactivity was achieved
Flrowlhoxpo F i '-F ' y F FFF Fi Inmoe '0eeltexperiment s swe selected libraries on
Ii o' 11 FatreFOH IV FIFe10'e[oeIy paFnFFiFF7directly on infected cells or antibody capI red viilT.Ie FF1 F po'entF 'cutliz[org Felibody was evil iled for in vivo efficacy in SCID
ic F r econsFt itte',i th 1Irerii P80s
Results: Large i iF [~rci'fIsec 'o-s6riot Iiuman antibodies 'e F live with many different opiii'pe (- theeeo peio HIV F haye heer generated fron' phago display lbraries. A broadFyrecivye ani:,p12 [F li indryg to)irntibody lormed g I b[2, which reutralizes a
A~i1 0 s of pFr i., 1 I,ts fHIV I (lde A through ') it biologically relevant conFenr F nwasi'dl '~Fl il' densirohtes hot broaidnualizilation of HIV- [ primary isoFes [I 1 Aosil F'h'oaFeFFnibdyTh itiody cao co'pletely protect fru-PBL SCID

I F c i F H ) c~ r t e l ' in it
v[1110'inF, Ve ii F'
Conclusions: A patel,
I I~he' lin theIN
F~n ol car'of i!11m0

'2/chaveFoe 0indications as to the origins of the potency
10n-t i'fF0ted elsuggests triat I u b 2 recognizes a eative
i; f120 morIFe effectively efanoether Ftibodies directed against
[F -' IF F IF IofFlhe exaFcI b 2-op tote fhas erportant implicatioes for
F L il 0 /F Fr F o' ry 0hu.e nirIbody agaiest HIV- I has been idetiF r' I I intie Ifht coniplete protection agaiest HIV- I infectiot cat
PhI 0'.113)irodol1y poasve inlrunidition with physiologically rolemo o FaFtbody[oThis irtibody isbeieg doveloped for immunon;fe yof[V, "fet"'o"'in FFm"nF'

N IF'lh Mrlo
RockviF'l'1MD 2

' it'1 I:'1 ( i' i 'IF, AI('_FfF1 I [F 'I!0, I F

Mo.A.272
ROLE OF FACTOR H IN RESISTANCE OF HIV AGAINST
COMPLEMENT-MEDIATED DESTRUCTION
Hierbetrt 5t ii. if C il' ic l'' n [d i Pi F ' 'F0 FFiir''Ali' Fc
P Uierfhlit lFlill0'I i Iii i 'F F "liI' 1 F
Ge-li dci I( i 1r'd"li li IlI' F [' l iF/
Objective: Iin '[1 F r y [i'( F F' BFi ll''F F F Ft ' 7+ i r 0''ricItI

["I' WI I [ rcPh.'D.,F Ie o cId'[p,Re eirch Iretilute, DopI oh Immoclogy,1066 North
"cEy f'in's P _(I d Id ' li JolFaCA 037,USA. ph (619)54.8602,
F~r! r;9 541' '1 [ iFt F q rppsi coo. 1 1,! d F

i it

the HIlV eivelop 01 vi 'F t,(
Methods'lHl bndig,.F f1('"i'
(SCR) d. t,',,pF )2) r. I-t ' ',
Inertoion ofr I II c:r Id ''
oi irn I Iy FAF S' N'1 FVl F F ' 1 c1
Results: We i" e I ',mItI F'
ist reF'FeF is l[c Fred I F 'i F l.F
rsnibtregi s i' F, FII F1 F. ii PIF.i U '
'frse 0 e[FO[ eI o un F F' ' F FII"'l)<,
calulte[a dI F( ill-c''
firi-r co' F in 'Fto the(' '' I [
Conclusions. Icr' 'F" F - 0 1F vIII
agairn I loplem enti F 0in' [ lei F ' (
peptides' der F[pF Ii ihll 1FF' I I l F
ed resiarce Fir tI y i Iii(a
development.F
Ackriow edyrF OF - irsu'd=dvFI 0 Fo
of Tyrol, by GtrirlllI. '[3 1 ofeV1
Saiti Insitlute Frai ii F t ini.Ie
Dr: lerlbert StouF ' 1FF'!iiiFl y:w:;;u'
f C ),

F ~i C l' - nv c I,i,'-). Id F ' 1 'P F
I/ Id F 'OW i i =tF' /1i ' F
I FH )pI [F 02 F F '[l Ii'e [[ ['7 HFMo
5 F[ale d( 1 ISA oiIVitF/11I? d riFlF
J'IBI 1v lI "1" [[[5 i f [F I' F 1
kite io 5tlr'! V. Ic F ree ( t'F F d l n
U F wn L1 1 l " '' 0 i ' '.r' ' 'I ' ii I ''0
Fn VII NtionFlFAllS PioectsMihr od(
F i ' Pi i' S r iA-00'0i' Rioi II', /J1 R

Mo.A.280
PHASE I/Il EVALUATION OF CANDIDATE AIDS VACCINES.
F1 rI FF8_BiriF' F' I' F rF1 3IAI1D'rVccie CliFFcF TriFFs Network.
Issue: (I )F'IF7 [FF1:>f ' i v' ii' 0 F ieF o r AIDF.
Project. II, I' At '' cI 1. F tir roupF /IsFFCsporsored by NIAIDOcoesits of 6
IF''~[F' FFite0' 2 'FntralabortoriesFa etrtal dati processieg and
F unit, '1 F 'pp Fit -o olItva cne cindidaites, evaluate safety and
'F F I F F 01a1ent 'd F' F' i ' F'yFnF-ds.IStudesIre tocusod on defieing the safety aed
11' un)enct cIiFOF ~FFFi f II an iti vacci110 10 identify vacinthoe strategies that are suffiintlyon I h' oFIFI, f offiay
'F' ~r. Results' '1h( hi)roleOr'0 DI. IF 'F' Flo iniviu[F i phse FanIVI Orroeel oalatFcanidaerALS accdualsce 98eThphhaisoluddlardealutio of1 ini
A lo ermI i acie F''. ' '1 V F F ind a viely of deliey vehicles, immunization routes
andscedle In o- U tdF0 ir.is [[1 estudies began by evlu Fing HIV- Isurface glycoprotein
F Flantiors elver-o ' F-rcitri F is Fi Foi'd recoembirnant proteins in sureThey have
IF' F eV IVO t Includei ~lu:' f ivde IaFcinie vector s, rovel delivery vehicles and adjuvants,
tr it Fn terna IF F F ' to F F FF71 'fIn FF7 at respoinsee isar importint componeet of the
it tr 111 Fe[ oriagim n 1.1 i-i F[ 01 0 inlude cylotoxioT ctllactivity and other ereasures of
colllaFr in n,uI' 'n ' i't,,-) F' >eO ogissays. Rather thin single product regimens. the
Lad osIs FoA 0n m'F l Ov cI 01e0vecorsFin cimbination vith other products used to
OFll LFb ostslected 'uop F OF Iot the irroune response. Coroposite data on immunologic
enFdpoints I einr F fe o- ' vacFinostraFlogieswilI be piresened, including instances of vaccine
faie irn which F 1 o - Iii' rrr oinFeod vvith HIV I dosp Fe mmnonization.
Lessons Learned: F' p ' s,,di arie developm~ent has comne in small increments, ard ultiint FlesFFs w 'IF' [F r,,;I OFitS Frarneg group7with diverse sciertific and scoot perspeol ye F '' 00' ' Fl I or ion oodernF vacciFeeconceits i0 humans, ard bosivestigaiotdefile ehaF F0nistsfor ducFing HIV- I immunity w 11 be needed.
B~i eyS.Grl-amA-331 Id I'd dOFF 'Uniersity Scoo f "MedcneNashvlleTN
F 2 2 6SP A

Mo.A.273

CROSS-CLADE NEUTRALIZATION OF HIV- I BY HOMOLOGOUS AND
HETEROLOGOUS SERA AND IDENTIFICATION OF THREE ISOLATES THAT
PREDICTS THE NEUTRALIZING CAPACITY OF SERA ACROSS HIVI CLADES.
Hit LPCI OliNLLodIPIFle t or '''' i >eiWFF~riFref.Po-sf r I'd. n'
Heoy' dir kx LF/i ln r' IF PII'.i. t"~ v '" n 1.i t ' F [ t I F i' 'i'
*Jirioresiirrl.n I )' I, Fir Il I,f' i'll ''F, IY~'IC F cE''
Objectives:1TO rsu dylIF rr''lfii 'F ' oh 'Ii 11 ': ~ i 01 1 I) 1 Oler ~IF ' lFF7'